Evidence map›Paper›PMID 38749660›Full record

ArticleJournal of clinical pathology2025

Combined analysis of albumin in situ hybridisation and C reactive protein immunohistochemistry for the diagnosis of intrahepatic cholangiocarcinoma: towards a molecular classification paradigm.

Thomas Albrecht, Annik Rossberg, Fabian Rose, Kai Breuhahn, Eva-Marie Baumann, Marcell Tóth, Fritz Brinkmann, Alphonse Charbel, Monika Nadja Vogel, Bruno Köhler and 8 more

Abstract read
In one paragraph

Article in Journal of clinical pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Thomas AlbrechtInstitute of Pathology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany Benjamin.Goeppert@rkh-gesundheit.de Thomas.Albrecht@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0002-2234-0909
Annik RossbergInstitute of Pathology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Fabian RoseInstitute of Pathology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Kai BreuhahnInstitute of Pathology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Eva-Marie BaumannInstitute of Pathology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Marcell TóthInstitute of Pathology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Fritz BrinkmannInstitute of Pathology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-6663-0940
Alphonse CharbelInstitute of Pathology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Monika Nadja VogelDepartment of Radiology and Nuclear Medicine, Robert Bosch Hospital Stuttgart, Stuttgart, Germany.
Bruno KöhlerLiver Cancer Center Heidelberg (LCCH), Heidelberg, Germany.
Arianeb MehrabiDepartment of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Markus Wolfgang BüchlerDepartment of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Stephan SingerInstitute of Pathology and Neuropathology, Eberhard Karls University, Tuebingen, Germany.
Wiebke SolassInstitute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
Beate StraubInstitute of Pathology, Johannes Gutenberg University, Mainz, Germany.
Peter SchirmacherInstitute of Pathology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Stephanie RoesslerInstitute of Pathology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-5333-5942
Benjamin GoeppertInstitute of Pathology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany Benjamin.Goeppert@rkh-gesundheit.de Thomas.Albrecht@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0002-4135-9250

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsIntrahepatic cholangiocarcinoma (iCCA) is a diagnosis of exclusion that can pose a challenge to the pathologist despite thorough clinical workup. Although several immunohistochemical markers have been proposed for iCCA, none of them reached clinical practice. We here assessed the combined usage of two promising diagnostic approaches, albumin in situ hybridisation (Alb-ISH) and C reactive protein (CRP) immunohistochemistry, for distinguishing iCCA from other adenocarcinoma primaries.

methodsWe conducted Alb-ISH and CRP immunohistochemistry in a large European iCCA cohort (n=153) and compared the results with a spectrum of other glandular adenocarcinomas of different origin (n=885). In addition, we correlated expression patterns with clinicopathological information and mutation data.

resultsAlb-ISH was highly specific for iCCA (specificity 98.8%) with almost complete negativity in perihilar CCA and only rare positives among other adenocarcinomas (sensitivity 69.5%). CRP identified the vast majority of iCCA cases (sensitivity 84.1%) at a lower specificity of 86.4%. Strikingly, the combination of CRP and Alb-ISH boosted the diagnostic sensitivity to 88.0% while retaining a considerable specificity of 86.1%. Alb-ISH significantly correlated with CRP expression, specific tumour morphologies and small or large duct iCCA subtypes. Neither Alb-ISH nor CRP was associated with iCCA patient survival. 16 of 17 recurrent mutations in either IDH1, IDH2 and FGFR2 affected Alb-ISH positive cases, while the only KRAS mutation corresponded to an Alb-ISH negative case.

conclusionsIn conclusion, we propose a sequential diagnostic approach for iCCA, integrating CRP immunohistochemistry and Alb-ISH. This may improve the accuracy of CCA classification and pave the way towards a molecular-guided CCA classification.

Indexed as

AlbuminsBile Duct NeoplasmsBiomarkers, TumorCholangiocarcinomaC-Reactive ProteinImmunohistochemistryIn Situ HybridizationAdenocarcinomaAdultAgedAged, 80 and overDiagnosis, DifferentialFemaleHumansMaleMiddle AgedAlbuminsBiomarkers, TumorC-Reactive ProteinBiliary TractCHOLANGIOCARCINOMADiagnostic Techniques and ProceduresIMMUNOHISTOCHEMISTRYPathology, Molecular

Identifiers

PMID38749660
PMCPMC12015024

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.